about
Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert™ MTB/RIF era: a cohort study.Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.Elevated Aspergillus-specific antibody levels among HIV infected Ugandans with pulmonary tuberculosis.Detection of tuberculosis patterns in digital photographs of chest X-ray images using Deep Learning: feasibility study.Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.Comparison of Löwenstein-Jensen and BACTEC MGIT 960 culture for Mycobacterium tuberculosis in people living with HIVHigh efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatmentHIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient ClinicTen years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohortA Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis PatientsPharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment OptionsThe Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH StudyAntiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control studySustained positive impact on tuberculosis treatment outcomes of TB-HIV integrated care in UgandaPharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosisImportance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland
P50
Q33808388-70C91CF7-2901-43CF-858F-B28F7CAA540DQ38851516-7C5EF322-DFBB-49A1-87B0-F0CF9C154199Q41996343-F96EAC25-0623-4E66-BC43-75F097A820F2Q47102823-191F3180-D0F5-46E7-B380-38282D5D4175Q50422265-3AECAD18-E31A-47E0-B59B-CAEA6DE689AFQ52669182-6F449CEB-B091-4EE9-8555-05012A784F13Q56908955-3F3B1EB6-6E5F-4E8D-88F8-A0CFBA0A0ADAQ56909387-596542AC-4E81-4DD4-9C96-74D6C5BEC591Q56910439-6BB25280-9E53-487F-85B1-2487152D5A5AQ58084945-D65F1733-2C34-4440-BA39-A25FC2DAE9DBQ64272805-39B4B713-D5D9-42A7-96FA-968315DE09BCQ89699857-516DDAD5-3258-46D3-9A7B-4B7511447089Q90998937-F692402D-0C9A-49F0-AF50-6C64F1597CA4Q91699232-1337BFB9-6112-4D94-962B-D71021B50D23Q91763469-EC725392-0AB5-4257-BC3D-415CD2F68119Q91830337-B43A3F49-3310-4A68-85D4-B756BD24D1A3Q92146416-41A97C59-A0B4-4C8F-8BD0-642C80C4E4DAQ93370271-D07BBAB2-D20C-4EE0-9FAB-4AEC861FC76E
P50
description
researcher
@en
wetenschapper
@nl
name
Christine Sekaggya-Wiltshire
@en
Christine Sekaggya-Wiltshire
@nl
type
label
Christine Sekaggya-Wiltshire
@en
Christine Sekaggya-Wiltshire
@nl
prefLabel
Christine Sekaggya-Wiltshire
@en
Christine Sekaggya-Wiltshire
@nl
P31
P496
0000-0001-9247-2950